The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases ...

South African lab technician Nozipho Mlotshwa was waiting for the test results for a potential HIV vaccine, which has eluded ...

According to data from amfAR, the Foundation for AIDS Research, about 1.3 million people are on HIV/AIDS treatment in Kenya, ...

Persistence of stigma toward people living with HIV has puzzled scientists looking at the numerous destigmatization campaigns ...

The decline in D.C. HIV cases is a positive trend, but funding cuts could impact future prevention work. Derrick “Strawberry” ...

The median (IQR) age of the people living with HIV (PLWH) was 49 (38-57) years, with the recently-arrived GBM having a median ...

One-shot’ approach that uses machine learning to screen immune cells could help to detect conditions with overlapping ...

A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

A team of researchers from the University of Florida has developed an innovative handheld device for human immunodeficiency virus (HIV) detection that combines paper-based sample preparation with real ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...